EdgarLookup

LENZ Therapeutics, Inc. — Insider Transactions

Form 4 filings by directors, officers, and 10%+ shareholders

SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.

Overview All Filings Annual Quarterly Insiders
Insider Title Type Shares Price Value Owns After Date
Olsson Shawn Chief Commercial Officer Sale 5,788 $26.37 $152,630 4,733 Nov 17, 2025
MCCOLLUM JAMES W Purchase 10,500 $22.79 $239,295 10,500 Nov 7, 2025
Chevallard Daniel R. Chief Financial Officer Purchase 20 $22.71 $454 3,208 Nov 7, 2025
Versant Vantage II GP-GP, LLC Sale 123 $47.01 $5,782 764,127 Sep 30, 2025
Versant Venture Capital VI, L.P. Sale 40,907 $43.00 $1,759,001 1,183,811 Sep 18, 2025
Versant Ventures VII GP, L.P. Sale 10,076 $40.03 $403,342 952,802 Aug 26, 2025
Versant Venture Capital VI, L.P. Sale 145,051 $39.50 $5,729,515 1,430,848 Aug 15, 2025
Versant Ventures VII GP-GP, LLC Sale 191,376 $34.00 $6,506,784 1,575,899 Jul 10, 2025
Versant Vantage II GP-GP, LLC Sale 200,000 $30.47 $6,094,000 1,767,275 Jun 27, 2025
Versant Ventures VI GP, L.P. Sale 133,924 $30.25 $4,051,201 1,967,275 Jun 20, 2025
Versant Vantage II GP-GP, LLC Sale 350,000 $29.00 $10,150,000 1,248,789 Jun 10, 2025
Olsson Shawn Chief Commercial Officer Option Exercise 1,400 $2.08 $2,912 4,733 Apr 9, 2025
Schimmelpennink Evert B. President, CEO and Secretary Option Exercise 4,200 $1.04 $4,368 49,200 Mar 7, 2025
Olsson Shawn Chief Commercial Officer Option Exercise 3,333 $2.08 $6,933 3,333 Dec 16, 2024
Schimmelpennink Evert B. President, CEO and Secretary Option Exercise 45,000 $1.04 $46,800 45,000 Jul 22, 2024
Chevallard Daniel R. Chief Financial Officer Purchase 3,188 $15.68 $49,988 3,188 May 14, 2024
MCCOLLUM JAMES W Purchase 31,332 $15.99 $500,999 525,565 May 13, 2024
RA Capital Nexus Fund II, L.P. Award / Grant 164,729 164,729 Mar 21, 2024
MCCOLLUM JAMES W Award / Grant 16,633 $15.03 $249,994 494,233 Mar 21, 2024
Odrich Marc Chief Medical Officer Award / Grant 99,599 99,599 Mar 21, 2024
Versant Vantage II GP, L.P. Other 598,203 842,162 Mar 21, 2024
AKKARAJU SRINIVAS Purchase 74,464 $4.07 $303,068 8,109,314 Apr 12, 2022
Gutry Phil CHIEF BUSINESS OFFICER Purchase 5,000 $4.01 $20,050 299,941 Apr 11, 2022
AKKARAJU SRINIVAS Purchase 100,000 $8.99 $899,000 8,011,850 Jan 24, 2022
AKKARAJU SRINIVAS Purchase 43,105 $8.92 $384,497 7,911,850 Jan 19, 2022
Samsara BioCapital, L.P. Purchase 22,329 $10.19 $227,533 7,814,180 Dec 15, 2021
AKKARAJU SRINIVAS Purchase 201,685 $10.15 $2,047,103 7,791,851 Nov 22, 2021
Samsara BioCapital, L.P. Purchase 45,400 $13.22 $600,188 7,584,766 Oct 15, 2021
AKKARAJU SRINIVAS Purchase 9,021 $14.94 $134,774 7,464,366 Oct 6, 2021
AKKARAJU SRINIVAS C 741,107 6,908,870 Jun 29, 2021
Lehrer-Graiwer Joshua PRESIDENT AND CEO Option Exercise 374,013 $0.30 $112,204 1,153,544 Jun 29, 2021
KARSEN PERRY A C 8,126 164,034 Jun 29, 2021
JIMENEZ JOSEPH Option Exercise 49,876 $0.30 $14,963 153,815 Jun 29, 2021
Shah Smital Purchase 5,882 $17.00 $99,994 5,882 Jun 29, 2021
Stultz Katherine V CHIEF OPERATING OFFICER C 8,126 216,020 Jun 29, 2021
Versant Vantage II GP-GP, LLC C 12,343,727 14,708,398 Jun 29, 2021
Jerel Davis C 1,527,719 1,527,719 Jun 29, 2021
Gutry Phil CHIEF BUSINESS OFFICER Option Exercise 91,406 $0.30 $27,422 281,962 Apr 18, 2021